These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10963219)

  • 1. PEP trial. Pulmonary Embolism Prevention.
    Smulders Y
    Lancet; 2000 Jul; 356(9225):248-9; author reply 250-1. PubMed ID: 10963219
    [No Abstract]   [Full Text] [Related]  

  • 2. PEP trial. Pulmonary Embolism Prevention.
    Cohen A; Quinlan D
    Lancet; 2000 Jul; 356(9225):247; author reply 250-1. PubMed ID: 10963215
    [No Abstract]   [Full Text] [Related]  

  • 3. PEP trial. Pulmonary Embolism Prevention.
    Kalsi GS
    Lancet; 2000 Jul; 356(9225):249; author reply 250-1. PubMed ID: 10963220
    [No Abstract]   [Full Text] [Related]  

  • 4. PEP trial. Pulmonary Embolism Prevention.
    Mahé I; Bergmann JF; Mahé E; Caulin C
    Lancet; 2000 Jul; 356(9225):248; author reply 250-1. PubMed ID: 10963217
    [No Abstract]   [Full Text] [Related]  

  • 5. PEP trial. Pulmonary Embolism Prevention.
    Cimminiello C
    Lancet; 2000 Jul; 356(9225):247-8; author reply 250-1. PubMed ID: 10963216
    [No Abstract]   [Full Text] [Related]  

  • 6. PEP trial. Pulmonary Embolism Prevention.
    Parker M
    Lancet; 2000 Jul; 356(9225):249; author reply 250-1. PubMed ID: 10963221
    [No Abstract]   [Full Text] [Related]  

  • 7. Aspirin for the treatment of pulmonary embolism: vasoconstriction versus physical obstruction.
    Poullis M
    Am Heart J; 2000 Oct; 140(4):E22. PubMed ID: 11011319
    [No Abstract]   [Full Text] [Related]  

  • 8. PEP trial. Pulmonary Embolism Prevention.
    Tauzeeh SM
    Lancet; 2000 Jul; 356(9225):248; author reply 250-1. PubMed ID: 10963218
    [No Abstract]   [Full Text] [Related]  

  • 9. PEP trial. Pulmonary Embolism Prevention.
    Thomas DP
    Lancet; 2000 Jul; 356(9225):249-50; author reply 250-1. PubMed ID: 10963222
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclooxygenase inhibition in patients with coronary artery disease.
    Frishman WH
    J Am Coll Cardiol; 2004 Feb; 43(4):532-3. PubMed ID: 14975459
    [No Abstract]   [Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.
    Lancet; 2000 Apr; 355(9212):1295-302. PubMed ID: 10776741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone therapy and risk for venous thromboembolism: comments and correction.
    Waitkevicz HJ; Axelrod D
    Ann Intern Med; 2001 Jan; 134(1):80-1. PubMed ID: 11187425
    [No Abstract]   [Full Text] [Related]  

  • 14. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
    Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin in the prevention and treatment of venous thromboembolism: a rebuttal.
    Maillardet L; Cohen AT
    J Thromb Haemost; 2007 Jan; 5(1):212-3; author reply 213-4. PubMed ID: 17239169
    [No Abstract]   [Full Text] [Related]  

  • 16. Venous thromboembolism after acute stroke.
    Sandercock P; Dennis M
    Stroke; 2001 Jun; 32(6):1443-8. PubMed ID: 11387512
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
    Bochner F; Lloyd J
    Clin Sci (Lond); 1986 Dec; 71(6):625-31. PubMed ID: 3098493
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of aspirin resistance.
    Floyd CN; Ferro A
    Pharmacol Ther; 2014 Jan; 141(1):69-78. PubMed ID: 23993980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terms and conditions: semantic complexity and aspirin resistance.
    Hennekens CH; Schror K; Weisman S; FitzGerald GA
    Circulation; 2004 Sep; 110(12):1706-8. PubMed ID: 15381661
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of antiaggregants in kidney diseases].
    Lapchyns'ka II; Dudar IO
    Lik Sprava; 1993; (10-12):14-20. PubMed ID: 8030297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.